key: cord-0966751-gz32wd2m
authors: Carugno, A.; Raponi, F.; Locatelli, A.G.; Vezzoli, P.; Gambini, D.M.; Di Mercurio, M.; Robustelli Test, E.; Sena, P.
title: No evidence of increased risk for COVID‐19 infection in patients treated with Dupilumab for atopic dermatitis in a high‐epidemic area ‐ Bergamo, Lombardy, Italy
date: 2020-04-27
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.16552
sha: 4f613996fa8166ff102bbc112127179342402084
doc_id: 966751
cord_uid: gz32wd2m

Atopic dermatitis (AD) is a chronic inflammatory skin disease. Patients with AD have increased infection risk, including skin infections and systemic infections. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin‐4 (IL‐4) and IL‐13. Dupilumab is approved for inadequately controlled moderate‐to‐severe AD.(1)

These days there is a significant amount of curiosity regarding the cutaneous manifestations COVID 19-related 5 

dermatology practice and to patients in therapy. 6, 7 We have decided to advise patients treated with biological drugs to scrupulously comply with hygiene rules and protective devices use, to avoid crowded places, to maintain social distancing and not to spontaneously suspend ongoing therapy but to inform the dermatologist in case of the onset of symptoms as suggested by the Italian Society of Dermatologists (SIDeMaST) 8 and by the European Task Force on Atopic Dermatitis (ETFAD). 9 We report below our experience with patients treated with biological therapy for atopic dermatitis in Bergamo, an area of high epidemic for COVID-19.

This article is protected by copyright. All rights reserved Our patients being treated with Dupilumab are residents in the provinces of Bergamo (n=25, 86.6%), Lecco (n=2, 6.7%), Brescia (n=1%, 3.3%), Monza-Brianza (n=1%, 3.3%), Sondrio (n=1, 3.3%), Lombardy areas with a high incidence of COVID-19 infections. 10 All patients (n=30, 20 males, 10 females, mean age 35.5±11.9 years, range 19-54 years) were Based on our experience, we observed that it is essential to advise and empower patients on activities to limit the risk of infection (hand hygiene, social distancing, use of protective devices), to report any symptoms to the dermatologist. Fortunately, no cases of COVID-19 infection in Dupilumab patients have been observed despite the high risk of contagion area.

The mechanism of action of the drug, the average age of the patients and the data of the randomized studies seem to reassure about the COVID-19 infectious risk that patients on Dupilumab therapy may have. Further observations on a larger number of patients receiving Dupilumab are needed to investigate the risk of COVID-19 infection.

A review of its use in the treatment of atopic dermatitis

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis

Critical care utilization for the COVID-19 outbreak in

Italy: early experience and forecast during an emergency response

Papa Giovanni XXIII Bergamo Hospital at the time of the COVID-19 outbreak: letter from the warfront

Accepted Article This article is protected by copyright. All rights reserved

Cutaneous manifestations in COVID-19: a first perspective

Art of performing dermoscopy during the times of coronavirus disease (COVID-19): Simple change in approach can save the day! J Eur Acad Dermatol Venereol

Biological treatment use amid the COVID-19 era, a close look at the unresolved perplexity

European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis